Merck & Co Inc
MRK82.750USD
+2.909+3.64%
收盘 04/25, 16:00（美东）报价延迟15分钟
209.16B总市值
12.22市盈率 TTM
关于 Merck & Co Inc 公司
默克公司是一家研究密集型生物制药公司，致力于研究提供健康解决方案，促进人类和动物疾病的预防和治疗。其制药部门包括人类健康药品和疫苗产品。人类健康药品包括治疗和预防药物，通常通过处方出售，用于治疗人类疾病。人类健康疫苗产品包括预防性儿童、青少年和成人疫苗。动物健康部门发现、开发、制造和销售一系列兽药和疫苗产品以及健康管理解决方案和服务，用于预防、治疗和控制所有主要牲畜和伴侣动物物种的疾病。该公司还致力于开发一类新型小分子，以缺乏关键 DNA 修复蛋白 O6-甲基鸟嘌呤甲基转移酶表达的癌细胞为目标。
公司简介
公司代码MRK
公司名称Merck & Co Inc
上市日期Jan 01, 1941
成立日期1970
CEOMr. Robert M. (Rob) Davis
员工数量75000
证券类型Ordinary Share
年结日Jan 01
公司地址126 East Lincoln Avenue
城市RAHWAY
上市交易所NYSE Consolidated
国家United States of America
邮编07065
电话19087404000
网址https://www.merck.com/
公司代码MRK
上市日期Jan 01, 1941
成立日期1970
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
20.72K
+5.86%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
地区USD
名称
营收
占比
United States
32.28B
50.30%
Europe, Middle East and Africa
14.04B
21.88%
China
5.49B
8.56%
Latin America
3.46B
5.39%
Japan
3.28B
5.11%
Other
5.62B
8.75%
业务
地区
业务USD
名称
营收
占比
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
股东统计
更新时间: 4月26日 周六
更新时间: 4月26日 周六
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Global Advisors (US)
4.80%
Wellington Management Company, LLP
3.21%
Geode Capital Management, L.L.C.
2.43%
Other
73.79%
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Global Advisors (US)
4.80%
Wellington Management Company, LLP
3.21%
Geode Capital Management, L.L.C.
2.43%
Other
73.79%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
36.08%
Investment Advisor
31.69%
Research Firm
3.57%
Pension Fund
2.96%
Bank and Trust
2.38%
Hedge Fund
1.53%
Sovereign Wealth Fund
1.49%
Insurance Company
0.69%
Family Office
0.11%
Other
19.49%
机构持股
更新时间: 2月20日 周四
更新时间: 2月20日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q1
5313
2.05B
81.04%
+16.06M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
2022Q4
4785
1.98B
77.94%
-5.23M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
253.26M
10.03%
+3.27M
+1.31%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
143.39M
5.68%
+10.26M
+7.71%
Dec 31, 2024
State Street Global Advisors (US)
120.91M
4.79%
+1.88M
+1.58%
Dec 31, 2024
Wellington Management Company, LLP
80.74M
3.2%
+4.93M
+6.51%
Dec 31, 2024
Geode Capital Management, L.L.C.
61.18M
2.42%
+2.03M
+3.43%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
34.98M
1.38%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
33.58M
1.33%
-11.95M
-26.24%
Dec 31, 2024
BofA Global Research (US)
23.08M
0.91%
-1.38M
-5.65%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
21.22M
0.84%
+1.34M
+6.77%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
20.63M
0.82%
-290.99K
-1.39%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
FT Vest DJIA Dogs 10 Target Income ETF
11.99%
First Trust NASDAQ Pharmaceuticals ETF
6.57%
VanEck Pharmaceutical ETF
5.04%
TBG Dividend Focus ETF
4.77%
Amplify Weight Loss Drug & Treatment ETF
4.76%
Invesco Pharmaceuticals ETF
4.51%
VictoryShares Free Cash Flow ETF
4.51%
Tema Oncology ETF
4.49%
Vaneck Durable High Dividend ETF
4.48%
Proshares Ultra Health Care
4.26%
查看更多
FT Vest DJIA Dogs 10 Target Income ETF
占比11.99%
First Trust NASDAQ Pharmaceuticals ETF
占比6.57%
VanEck Pharmaceutical ETF
占比5.04%
TBG Dividend Focus ETF
占比4.77%
Amplify Weight Loss Drug & Treatment ETF
占比4.76%
Invesco Pharmaceuticals ETF
占比4.51%
VictoryShares Free Cash Flow ETF
占比4.51%
Tema Oncology ETF
占比4.49%
Vaneck Durable High Dividend ETF
占比4.48%
Proshares Ultra Health Care
占比4.26%
分红派息
近5年累计派现
35.12B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据